Neuropathic Pain: Unexplored and Significant Relationship With Psoriatic Arthritis and Functional Parameters

Çağrı Ünal ULUTATAR, Fırat ULUTATAR, Mehmet Tuncay DURUÖZ

DOI: 10.46497/ArchRheumatol.2020.7215

Issue: Volume 35 - Issue 3 - September 2020
2689 2020

Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs

Yaşar KESKİN, Kemal NAS, Erkan KILIÇ, Betul SARGIN, Sevtap ACER KASMAN, Hakan ALKAN, Nilay ŞAHİN, Gizem CENGİZ, Nihan CUZDAN, İlknur ALBAYRAK GEZER, Dilek KESKİN, Cevriye MÜLKOĞLU, Hatice RESORLU, Şebnem ATAMAN, Ajda BAL, Mehmet Tuncay DURUOZ, Okan KÜÇÜKAKKAS, Ozan Volkan YURDAKUL, Meltem ALKAN MELİKOĞLU, Yıldıray AYDIN, F. Figen AYHAN, Hatice BODUR, Mustafa ÇALIŞ, Erhan ÇAPKIN, Gül DEVRİMSEL, Kevser GÖK, Sami HİZMETLİ, Ayhan KAMANLI, Hilal ECESOY, Öznur KUTLUK, Nesrin ŞEN, Ömer Faruk ŞENDUR, İbrahim TEKEOĞLU, Sena TOLU, Murat TOPRAK, Tiraje TUNCER

DOI: 10.46497/ArchRheumatol.2021.7874

Issue: Volume 36 - Issue 1 - March 2021
2101 2710

Assessment of subclinical atherosclerosis with ankle-brachial index in psoriatic arthritis: A case-control study

Serhad BİLİM, Afitap İÇAĞASIOĞLU, Ayla AKBAL, Esen KASAPOĞLU, Sıdıka GÜRSEL

DOI: 10.46497/ArchRheumatol.2021.8083

Issue: Volume 36 - Issue 2 - June 2021
1656 1970

Validity and reliability of the Turkish version of Psoriasis Epidemiology Screening Tool for the detection of psoriatic arthritis in patients with psoriasis

Serdar Kaymaz, Uğur Karasu, Nida Kaçar, Hakan Alkan

DOI: 10.46497/ArchRheumatol.2022.8221

Issue: Volume 37 - Issue 4 - December 2022
1516 1353

Examining the functions of the vascular endothelial growth factor/hypoxia-inducible factor signaling pathway in psoriatic arthritis

Yavuz Kiliç, Derya Guzel Erdogan, Merve Baykul, Kemal Nas

DOI: 10.46497/ArchRheumatol.2023.9898

Issue: Volume 38 - Issue 4 - December 2023
1358 936

Risk of flare in juvenile idiopathic arthritis: Is it related to the methotrexate treatment strategy or patient characteristics?

Rana İşgüder, Zehra Kızıldağ, Rüya Torun, Tuncay Aydın, Balahan Makay, Erbil Ünsal

DOI: 10.46497/ArchRheumatol.2023.10035

Issue: Volume 38 - Issue 4 - December 2023
1042 821

Secukinumab after first-line tumor necrosis factor-alpha inhibitor therapy in psoriatic arthritis: A real-world retrospective cohort study

Tumay Ak, Leyla Mustafayeva, Ali Yagiz Ayla, Yeliz Celik, Gunay Can, Serdal Ugurlu

DOI: 10.46497/ArchRheumatol.2024.10050

Issue: Volume 39 - Issue 1 - March 2024
1285 845